These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32913286)

  • 21. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
    Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
    Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
    Dolly SO; Wagner AJ; Bendell JC; Kindler HL; Krug LM; Seiwert TY; Zauderer MG; Lolkema MP; Apt D; Yeh RF; Fredrickson JO; Spoerke JM; Koeppen H; Ware JA; Lauchle JO; Burris HA; de Bono JS
    Clin Cancer Res; 2016 Jun; 22(12):2874-84. PubMed ID: 26787751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
    Boss DS; Schwartz GK; Middleton MR; Amakye DD; Swaisland H; Midgley RS; Ranson M; Danson S; Calvert H; Plummer R; Morris C; Carvajal RD; Chirieac LR; Schellens JHM; Shapiro GI
    Ann Oncol; 2010 Apr; 21(4):884-894. PubMed ID: 19825886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
    Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
    Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
    Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
    Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
    J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
    Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
    Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
    Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
    Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
    J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
    Starks DC; Rojas-Espaillat L; Meissner T; Williams CB
    Gynecol Oncol; 2022 Sep; 166(3):403-409. PubMed ID: 35843739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
    Rasco DW; Medina T; Corrie P; Pavlick AC; Middleton MR; Lorigan P; Hebert C; Plummer R; Larkin J; Agarwala SS; Daud AI; Qiu J; Bozon V; Kneissl M; Barry E; Olszanski AJ
    Cancer Chemother Pharmacol; 2023 Jul; 92(1):15-28. PubMed ID: 37219686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.